Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Determine the Safety and Tolerability of BI 3820768 in Patients With Advanced Relapsed or Refractory Germ Cell Tumours, Endometrial Cancer, or Ovarian Cancer

NCT07306559 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07306559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07306559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Determine the Safety and Tolerability of BI 3820768 in Patients With Advanced Relapsed or Refractory Germ Cell Tumours, Endometrial Cancer, or Ovarian Cancer
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Recruiting
Start date
February 27, 2026
Completion date
January 28, 2030
Enrollment
187 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced relapsed or refractory endometrial cancer, advanced relapsed or refractory germ cell tumours, advanced relapsed or refractory ovarian cancer